tremelimumab,durvalumab,sorafenib
astrazeneca,bayer
[]
#gi23 #clinicaltrials the stride t300 d regimen or the himalaya regimen in hcc studied in dmmr/msi-high. #ctdna &amp; pathologic complete response as endpoints. a small #chalabiplot 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22